TALIS INVESTOR ALERT: Kaplan Fox Investigates Potential Securities Fraud at Talis Biomedical

NEXT STORY
Avalo Therapeutics Appoints Stephen Smolinski as Chief Commercial Officer
PREV STORY
Sana Biotechnology, IASO Biotherapeutics, and Innovent Biologics Announce Non-Exclusive License Agreement for Clinically Validated BCMA CAR Construct
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Interpace Diagnostics Announces Agreement with Acupath Laboratories

PARSIPPANY, N.J., March 28, 2018 (GLOBE NEWSWIRE) -- Interpace Diagnostics Group, Inc. (NASDAQ:IDXG) (“Interpace” ...

author_avatar
NASDAQ Market News

Pluristem Provides Fiscal Year 2016 Corporate and Financial Highlights

Executing an efficient commercialization strategy with  three planned late stage pivotal trials Innovative regulatory pathway ...

author_avatar
NASDAQ Market News

Mesa Labs Reports First Quarter Results

author_avatar
NASDAQ Market News